The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Nelarabine for R/R T-cell ALL
Robin Foà
• 15 Jun 2019
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses a phase IIII study investigating nelarabine as salvage and bridging therapy to allogeneic stem-cell transplantation in adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia(ALL). This interview was held at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
